Status:
ACTIVE_NOT_RECRUITING
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
Lead Sponsor:
State University of New York at Buffalo
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Primary Progressive Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Brief Summary
The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflamm...
Detailed Description
To study the effect of ocrelizumab on choroid plexus changes in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomized, p...
Eligibility Criteria
Inclusion
- Patient participating in the ORATORIO study
- MRI scans available at baseline
- Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 3D T1-WI at baseline
Exclusion
- \- None
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
732 Patients enrolled
Trial Details
Trial ID
NCT05974852
Start Date
October 1 2023
End Date
December 30 2025
Last Update
February 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Buffalo Neuroimaging Analysis Center
Buffalo, New York, United States, 14203